-
EP2555771
European procedure
Extract from the Register of European Patents
EP About this file: EP2555771
| EP2555771 - PHARMACEUTICAL COMPOSITIONS STRONGLY DOSED IN BIOTINE [Right-click to bookmark this link] | |||
| Former [2013/07] | PHARMACEUTICAL COMPOSITIONS HIGHLY DOSED WITH BIOTIN | ||
| [2016/37] | Status | No opposition filed within time limit Status updated on 29.09.2017 Database last updated on 31.03.2026 | Most recent event Tooltip | 29.09.2017 | No opposition filed within time limit | published on 01.11.2017 [2017/44] | Applicant(s) | For all designated states Assistance Publique - Hôpitaux de Paris 3 Avenue Victoria 75004 Paris / FR | [2016/38] |
| Former [2013/07] | For all designated states Assistance Publique Hôpitaux De Paris 3 Avenue Victoria 75004 Paris / FR | Inventor(s) | 01 /
SEDEL, Frédéric 17 rue des rigoles F-75020 Paris / FR | 02 /
BELLANGER, Agnès 73 boulevard de Montparnasse F-75006 Paris / FR | [2013/07] | Representative(s) | Flesselles, Bruno F.G. BF IP 36 rue Jean de la Fontaine 75016 Paris / FR | [2016/47] |
| Former [2013/07] | Flesselles, Bruno F.G. Caninet BF IP 4, rue Ribera 75016 Paris / FR | Application number, filing date | 11714252.1 | 05.04.2011 | [2016/47] | WO2011EP55273 | Priority number, date | FR20100052589 | 06.04.2010 Original published format: FR 1052589 | [2013/07] | Filing language | FR | Procedural language | FR | Publication | Type: | A1 Application with search report | No.: | WO2011124571 | Date: | 13.10.2011 | Language: | FR | [2011/41] | Type: | A1 Application with search report | No.: | EP2555771 | Date: | 13.02.2013 | Language: | FR | The application published by WIPO in one of the EPO official languages on 13.10.2011 takes the place of the publication of the European patent application. | [2013/07] | Type: | B1 Patent specification | No.: | EP2555771 | Date: | 23.11.2016 | Language: | FR | [2016/47] | Search report(s) | International search report - published on: | EP | 13.10.2011 | Classification | IPC: | A61K31/4188, A61P27/02 | [2013/07] | CPC: |
A61K31/4188 (EP,US);
A61K31/407 (US);
A61P27/00 (EP);
A61P27/02 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2013/07] | Extension states | BA | Not yet paid | ME | Not yet paid | Title | German: | PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT HÖHER DOSIERUNG IN BIOTINE | [2016/37] | English: | PHARMACEUTICAL COMPOSITIONS STRONGLY DOSED IN BIOTINE | [2016/37] | French: | COMPOSITIONS PHARMACEUTIQUES FORTEMENT DOSEES EN BIOTINE | [2013/07] |
| Former [2013/07] | MIT BIOTIN HOCHDOSIERTE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN | ||
| Former [2013/07] | PHARMACEUTICAL COMPOSITIONS HIGHLY DOSED WITH BIOTIN | Entry into regional phase | 08.10.2012 | National basic fee paid | 08.10.2012 | Designation fee(s) paid | 08.10.2012 | Examination fee paid | Examination procedure | 08.10.2012 | Examination requested [2013/07] | 06.06.2013 | Amendment by applicant (claims and/or description) | 30.06.2015 | Despatch of a communication from the examining division (Time limit: M06) | 04.01.2016 | Reply to a communication from the examining division | 25.08.2016 | Communication of intention to grant the patent | 17.10.2016 | Fee for grant paid | 17.10.2016 | Fee for publishing/printing paid | 17.10.2016 | Receipt of the translation of the claim(s) | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 30.06.2015 | Opposition(s) | 24.08.2017 | No opposition filed within time limit [2017/44] | Fees paid | Renewal fee | 24.04.2013 | Renewal fee patent year 03 | 24.04.2014 | Renewal fee patent year 04 | 27.04.2015 | Renewal fee patent year 05 | 25.04.2016 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Licence(s) | ID: | 01 01/exclusive | For: | AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR | Licencee: | MEDDAY 26 rue des Rigoles 75020 Paris / FR | Date: | 22.07.2014 | [2014/37] | Lapses during opposition Tooltip | deleted | [2017/13] |
| Former [2017/12] | LV | 23.11.2016 | Cited in | International search | [XA] WEBER PETER ET AL: "Outcome in patients with profound biotinidase deficiency: relevance of newborn screening", DEVELOPMENTAL MEDICINE & CHILD NEUROLOGY, vol. 46, no. 7, July 2004 (2004-07-01), pages 481 - 484, XP008126454, ISSN: 0012-1622 DOI: http://dx.doi.org/10.1111/j.1469-8749.2004.tb00509.x | [X] RAHMAN SHAMIMA ET AL: "Late presentation of biotinidase deficiency with acute visual loss and gait disturbance", DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, vol. 39, no. 12, December 1997 (1997-12-01), pages 830 - 831, XP008126455, ISSN: 0012-1622 DOI: http://dx.doi.org/10.1111/j.1469-8749.1997.tb07552.x | [X] YANG YANLING ET AL: "Spinal cord demyelination associated with biotinidase deficiency in 3 Chinese patients", JOURNAL OF CHILD NEUROLOGY, vol. 22, no. 2, February 2007 (2007-02-01), pages 156 - 160, XP008126453, ISSN: 0883-0738 DOI: http://dx.doi.org/10.1177/0883073807300307 | [A] PUERTAS BORDALLO D ET AL: "[Optic neuropathy in biotinidase deficiency]", ARCHIVOS DE LA SOCIEDAD ESPAOLA DE OFTALMOLOGA AUG 2004 LNKD- PUBMED:15306966, vol. 79, no. 8, August 2004 (2004-08-01), pages 393 - 396, XP008126451, ISSN: 0365-6691 | [X] DATABASE WPI Week 199724, Derwent World Patents Index; AN 1997-267712, XP002599161 | by applicant | DABBAGH 0, BRISMAR J, GASCON GG, OZAND PT: "The clinical spectrum of biotin- treatable encephalopathies in Saudi Arabia", BRAIN DEV., vol. 16, 1994, pages 72 - 80, XP024397613, DOI: doi:10.1016/0387-7604(94)90099-X DOI: http://dx.doi.org/10.1016/0387-7604(94)90099-X | DEBS R, DEPIENNE C, RASTETTER A, BELLANGER A, DEGOS B, GALANAUD D, KEREN B, LYON-CAEN 0, BRICE A, SEDEL F: "Biotin-Responsive Basal Ganglia Disease (BBGD) in Europeans with novel SLC19A3 mutations", ARCH NEUROL., vol. 67, no. 1, January 2010 (2010-01-01), pages 126 - 30 | OZAND PT, GASCON GG, AI ESSA M, JOSHI S, AI JISHI E, BAKHEET S, AI WATBAN J, AI-KAWI MZ, DABBAGH O: "Biotin-responsive basal ganglia disease: a novel entity", BRAIN., vol. 121, July 1998 (1998-07-01), pages 1267 - 79 | RAMAEKERS VT, BRAB M, RAU G, HEIMANN G.: "Recovery from neurological deficits following biotin treatment in a biotinidase Km variant", NEUROPEDIATRICS, vol. 24, 1993, pages 98 - 102, XP008126439, DOI: doi:10.1055/s-2008-1071522 DOI: http://dx.doi.org/10.1055/s-2008-1071522 | SEDEL F, TOURBAH A, FONTAINE B, LUBETZKI C, BAUMANN N, SAUDUBRAY JM, LYON-CAEN O: "Leukoencephalopathies associated with Inborn Errors of Metabolism in adults: a diagnostic approach", J INHERIT METAB DIS., vol. 31, no. 3, June 2008 (2008-06-01), pages 295 - 307 | SUBRAMANIAN VS, MARCHANT JS, SAID HM: "Biotin-responsive basal ganglia disease- linked mutations inhibit thiamine transport via hTHTR2 : biotin is not a substrate for hTHTR2", AM J PHYSIOL., vol. 291, no. 5, 2006, pages 851 - 859 | VLASOVA TI, STRATTON SL, WELLS AM, MOCK NI, MOCK DM: "Biotin deficiency reduces expression of SLC19A3, a potential biotin transporter, in leukocytes from human blood", J NUTR., vol. 135, no. 1, 2005, pages 42 - 47 | WOLF B, POMPONIO RJ, NORRGARD KJ, LOTT IT, BAUMGARTNER ER, SUORMALA T, RAMAEKERS VT, COSKUN T, TOKATLI A, OZALP, J PEDIATR., vol. 132, no. 2, 1998, pages 362 - 5 | ZEMPLENI J, WIJERATNE SS, HASSAN YI, BIOTIN. BIOFACTORS, vol. 35, no. 1, 2009, pages 36 - 46 | ZENG WQ, AI-YAMANI E, ACIERNO JS JR ET AL.: "Biotin-responsive basal ganglia diease maps to 2q36.3 and is due to mutations in SCL19A3", AM J HUM GENET, vol. 77, no. 1, 2005, pages 16 - 26 |